drugset / Trial / NCT00284739

Alteplase for Percutaneous Treatment of Loculated Abdominopelvic Abscesses

NCT00284739

Phase 2 Completed 20 enrolled Kaiser Permanente Genentech, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Intracavitary injection of low dose alteplase into loculated abdominopelvic abscesses will reduce the duration of percutaneous drainage and increase the proportion of successful drainages.

Timeline

Start
2006-02
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Alteplase Protein / enzyme biologic 2 mg Other
Subject Alteplase Protein / enzyme biologic 4 mg Other

Indications